Compare BAC & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BAC | MRK |
|---|---|---|
| Founded | 1784 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 346.2B | 317.8B |
| IPO Year | 2025 | 1997 |
| Metric | BAC | MRK |
|---|---|---|
| Price | $49.61 | $146.63 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 25 | 28 |
| Target Price | $62.48 | ★ $161.53 |
| AVG Volume (30 Days) | ★ 39.2M | 7.6M |
| Earning Date | 10-14-2026 | 10-29-2026 |
| Dividend Yield | ★ 2.57% | 2.31% |
| EPS Growth | ★ 18.69 | 8.01 |
| EPS | ★ 3.23 | N/A |
| Revenue | ★ $113,097,000,000.00 | $65,011,000,000.00 |
| Revenue This Year | $8.38 | $3.39 |
| Revenue Next Year | $6.20 | $3.32 |
| P/E Ratio | $15.98 | ★ N/A |
| Revenue Growth | ★ 11.00 | 1.31 |
| 52 Week Low | $46.12 | $85.80 |
| 52 Week High | $65.23 | $157.00 |
| Indicator | BAC | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 36.22 | 51.26 |
| Support Level | $49.28 | $145.75 |
| Resistance Level | $54.84 | $154.35 |
| Average True Range (ATR) | 1.12 | 4.58 |
| MACD | 0.20 | 0.25 |
| Stochastic Oscillator | 15.82 | 50.50 |
Bank of America is a formidable financial titan with a $3.43 trillion balance sheet and a cornerstone of the American economy, holding the second-largest deposit market share in the United States. While the firm has maintained its stronghold among middle-market and retail clientele domestically, Bank of America has continued to hold its own on the global stage, as evidenced by its fourth-largest global trading operation and an investment banking division that regularly finishes in the top four in global league tables. The firm is organized across four segments: consumer banking, global wealth and investment management, global banking, and global markets.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).